485 related articles for article (PubMed ID: 23818340)
41. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
[TBL] [Abstract][Full Text] [Related]
42. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
43. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
44. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
45. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
46. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
[TBL] [Abstract][Full Text] [Related]
47. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
48. SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
Collie-Duguid ES; Sweeney K; Stewart KN; Miller ID; Smyth E; Heys SD
Breast Cancer Res Treat; 2012 Apr; 132(3):807-18. PubMed ID: 21695460
[TBL] [Abstract][Full Text] [Related]
49. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
50. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
De Laurentiis M; Cancello G; D'Agostino D; Giuliano M; Giordano A; Montagna E; Lauria R; Forestieri V; Esposito A; Silvestro L; Pennacchio R; Criscitiello C; Montanino A; Limite G; Bianco AR; De Placido S
J Clin Oncol; 2008 Jan; 26(1):44-53. PubMed ID: 18165639
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
[TBL] [Abstract][Full Text] [Related]
52. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
Bamias A; Karina M; Papakostas P; Kostopoulos I; Bobos M; Vourli G; Samantas E; Christodoulou Ch; Pentheroudakis G; Pectasides D; Dimopoulos MA; Fountzilas G
Cancer Chemother Pharmacol; 2010 May; 65(6):1009-21. PubMed ID: 20130877
[TBL] [Abstract][Full Text] [Related]
53. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
54. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
55. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
56. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
57. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
58. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
Chirivella I; Bermejo B; Insa A; Pérez-Fidalgo A; Magro A; Rosello S; García-Garre E; Martín P; Bosch A; Lluch A
Breast Cancer Res Treat; 2009 Apr; 114(3):479-84. PubMed ID: 18463977
[TBL] [Abstract][Full Text] [Related]
59. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
Mavroudis D; Saloustros E; Boukovinas I; Papakotoulas P; Kakolyris S; Ziras N; Christophylakis C; Kentepozidis N; Fountzilas G; Rigas G; Varthalitis I; Kalbakis K; Agelaki S; Hatzidaki D; Georgoulias V
Br J Cancer; 2017 Jul; 117(2):164-170. PubMed ID: 28641315
[TBL] [Abstract][Full Text] [Related]
60. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
